Nexvax2 development program
Nexpep is committed to keeping its investors updated on the progress of the Nexvax2 development program. Potential investors are welcome to contact us for more information.
To date, the following stages have been completed successfully:
1. Pre-clinical program completed
2. cGMP drug manufacture completed
3. PK and Toxicology conducted
4. Phase I clinical trial design formalised
5. Investigator Brochure completed
6. Ethics application approved
7. First in human study commenced in April 2009
Nexpep's collaborative partners are:
The Walter and Eliza Hall Institute of Medical Research
www.wehi.edu.au
The Royal Melbourne Hospital
/ Melbourne Health
www.mh.org.au
INOVA Diagnostic Inc.
www.inovadx.com